Cited by 184Schizophrenia research and treatmentNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.

Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications

Open access

Coyle, Joseph T., Basu, Alo, Benneyworth, Michael, Balu, Darrick, Konopaske, Glenn·2012·Handbook of Experimental Pharmacology

DOI 10.1007/978-3-642-25758-2_10PMC PMC4817347

Open this paper in CoChat — free account

Abstract

Schizophrenia affects approximately 1% of the population and continues to be associated with poor outcome because of the limited efficacy of and noncompliance with existing antipsychotic medications. An alternative hypothesis invoking the excitatory neurotransmitter, glutamate, arose out of clinical observations that NMDA receptor antagonists, the dissociative anesthetics like ketamine, can replicate in normal individuals the full range of symptoms of schizophrenia including psychosis, negative symptoms, and cognitive impairments. Low dose ketamine can also re-create a number of physiologic abnormalities characteristic of schizophrenia. Postmortem studies have revealed abnormalities in endogenous modulators of NMDA receptors in schizophrenia as well as components of a postsynaptic density where NMDA receptors are localized. Gene association studies have revealed several genes that affect NMDA receptor function whose allelic variants are associated with increased risk for schizophrenia including genes encoding D-amino acid oxidase, its modulator G72, dysbindin, and neuregulin. The parvalbumin-positive, fast-firing GABAergic interneurons that provide recurrent inhibition to cortical-limbic pyramidal neurons seem to be most sensitive to NMDA receptor hypofunction. As a consequence, disinhibition of glutamatergic efferents disrupts cortical processing, causing cognitive impairments and negative symptoms, and drives subcortical dopamine release, resulting in psychosis. Drugs designed to correct the cortical-limbic dysregulated glutamatergic neurotransmission show promise for reducing negative and cognitive symptoms of schizophrenia as well as its positive symptoms.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/978-3-642-25758-2_10

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,182
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies
BRAFF, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,701
Decreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Rare chromosomal deletions and duplications increase risk of schizophrenia
The International Schizophrenia Consortium (2008) · Nature · doi:10.1038/nature07239 · Cited by 1,475
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
Whitfield-Gabrieli, S., Thermenos, H. W., Milanovic, S., Tsuang, M. T., Faraone, S. V., McCarley, R. W., Shenton, M. E., Green, A. I., Nieto-Castanon, A., LaViolette, P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809141106 · Cited by 1,435
Requirement for Glycine in Activation of NMDA-Receptors Expressed in Xenopus Oocytes
Kleckner, N. W., & Dingledine, R. J. (1988) · Science · doi:10.1126/science.2841759 · Cited by 1,427
The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231
Translating developmental time across mammalian species
Clancy, B., Darlington, R. B., & Finlay, B. L. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00171-3 · Cited by 1,221
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia
Hakak, Y., Walker, J. R., Li, C., Wong, W. H., Davis, K. L., Buxbaum, J. D., Haroutunian, V., & Fienberg, A. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081071198 · Cited by 1,192
Prestimulus Effects on Human Startle Reflex in Normals and Schizophrenics
BRAFF, D. L., Stone, C., Callaway, E., Geyer, M. A., Glick, I. D., & Bali, L. (1978) · Psychophysiology · doi:10.1111/j.1469-8986.1978.tb01390.x · Cited by 1,171
Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia
Jones, P. B., Barnes, T. R. E., Davies, L. M., Dunn, G., Lloyd, H. M., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,112
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database
Allen, N. C., Bagade, S., McQueen, M. B., Ioannidis, J. P. A., Kavvoura, F. K., Khoury, M. J., Tanzi, R. E., & Bertram, L. (2008) · Nature Genetics · doi:10.1038/ng.171 · Cited by 1,054
Modulation of Neuronal Migration by NMDA Receptors
Komuro, H., & RAKIC, P. T. (1993) · Science · doi:10.1126/science.8096653 · Cited by 1,041
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Neuregulin 1 in neural development, synaptic plasticity and schizophrenia
Mei, L., & Xiong, W.-C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2392 · Cited by 1,030
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,022
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
Self-citation
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.
Akbarian, S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160008002 · Cited by 1,002
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors
Harris, E. W., Ganong, A. H., & Cotman, C. W. (1984) · Brain Research · doi:10.1016/0006-8993(84)90275-0 · Cited by 905
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Dopamine receptors and the dopamine hypothesis of schizophrenia
Seeman, P. M. (1987) · Synapse · doi:10.1002/syn.890010203 · Cited by 880
The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications
Hilmas, C. J., Pereira, E. F. R., Alkondon, M., Rassoulpour, A., Schwarcz, R. M., & Albuquerque, E. X. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07463.2001 · Cited by 875
Genetic and physiological data implicating the new human gene G72 and the gene for d -amino acid oxidase in schizophrenia
Chumakov, I. M., BLUMENFELD, M. L., Guerassimenko, O., Cavarec, L., Palicio, M., Abderrahim, H., Bougueleret, L., Barry, C., Tanaka, H., Rosa, P. L., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412499 · Cited by 834
D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release
Schell, M. J., Molliver, M. E., & Snyder, S. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3948 · Cited by 832
Serine racemase: A glial enzyme synthesizing d -serine to regulate glutamate- N -methyl- d -aspartate neurotransmission
Wolosker, H., Blackshaw, S., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13409 · Cited by 811
Two Forms of the γ‐Aminobutyric Acid Synthetic Enzyme Glutamate Decarboxylase Have Distinct Intraneuronal Distributions and Cofactor Interactions
Kaufman, D. L., Houser, C. R., & Tobin, A. J. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb08211.x · Cited by 789
Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology
TANDON, R., Keshavan, M. S., & Nasrallah, H. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.04.011 · Cited by 770
A review of diffusion tensor imaging studies in schizophrenia
Kubicki, M., McCarley, R., Westin, C.-F., Park, H.-J., Maier, S., Kikinis, R., Jolesz, F. A., & Shenton, M. E. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.05.005 · Cited by 769
Impulse activity and the patterning of connections during cns development
Shatz, C. J. (1990) · Neuron · doi:10.1016/0896-6273(90)90333-b · Cited by 766
A decrease of reelin expression as a putative vulnerability factor in schizophrenia
Impagnatiello, F., Guidotti, A. R., Pesold, C., Dwivedi, Y., Caruncho, H. J., Pisu, M. G., Uzunov, D. P., Smalheiser, N. R., Davis, J. M., Pandey, G. N., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15718 · Cited by 762
Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia
Garey, L. J., Ong, W., Patel, T. S., Kanani, M., Davis, A., Mortimer, A. M., Barnes, T., & Hirsch, S. R. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.4.446 · Cited by 719
Decreased Glutamic Acid Decarboxylase67 Messenger RNA Expression in a Subset of Prefrontal Cortical γ-Aminobutyric Acid Neurons in Subjects With Schizophrenia
Volk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.237 · Cited by 697
Synaptogenesis in the Prefrontal Cortex of Rhesus Monkeys
Bourgeois, J.-P., Goldman-Rakic, P. S., & Rakic, P. (1994) · Cerebral Cortex · doi:10.1093/cercor/4.1.78 · Cited by 687
Altered Distribution of Nicotinamide-Adenine Dinucleotide Phosphate—Diaphorase Cells in Frontal Lobe of Schizophrenics Implies Disturbances of Cortical Development
Akbarian, S. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820150007001 · Cited by 680
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y., & Chong, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 676
Effects of Ketamine in Normal and Schizophrenic Volunteers
Lahti, A. C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00243-3 · Cited by 674
A Separate Disease Within the Syndrome of Schizophrenia
Kirkpatrick, B. W., Buchanan, R. W., Ross, D. E., & Carpenter, W. T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.2.165 · Cited by 651
The Economic Burden of Schizophrenia in the United States in 2002
Wu, E. Q., Birnbaum, H. G., Shi, L., BALL, D. E., Kessler, R. C., Moulis, M., & Aggarwal, J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0906 · Cited by 614
Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
Newcomer, J. W. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00067-0 · Cited by 611
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers
Umbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., & Javitt, D. C. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1139 · Cited by 587
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585
D-serine added to antipsychotics for the treatment of schizophrenia
Tsai, G. E., Yang, P., Chung, L.-C., LANGE, N. D., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 572
Self-citation
Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia
Hahn, C.-G., Wang, H.-Y., Cho, D.-S., Talbot, K., Gur, R. E., Berrettini, W. H., Bakshi, K. P., Kamins, J., Borgmann‐Winter, K. E., Siegel, S. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1418 · Cited by 564
NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury
Salter, M. G., & Fern, R. F. (2005) · Nature · doi:10.1038/nature04301 · Cited by 556
Progressive Structural Brain Abnormalities and Their Relationship to Clinical Outcome
Ho, B., Andreasen, N. C., Nopoulos, P., Arndt, S. V., Magnotta, V. A., & Flaum, M. A. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.585 · Cited by 536
Purification of serine racemase: biosynthesis of the neuromodulator D-serine.
Wolosker, H., Sheth, K., Takahashi, M., Mothet, J., Brady, R., Ferris, C., & Snyder, S. (1999) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.96.2.721 · Cited by 505
Local circuit neurons immunoreactive for calretinin, calbindin D‐28k or parvalbumin in monkey prefronatal cortex: Distribution and morphology
Condé, F., Lund, J. S., Jacobowitz, D. M., Baimbridge, K. G., & Lewis, D. A. (1994) · The Journal of Comparative Neurology · doi:10.1002/cne.903410109 · Cited by 500
Effects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work
Davis, M., Ressler, K., Rothbaum, B. O., & Richardson, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.084 · Cited by 498 · cited 2×
“However interventions that enhance NMDA receptor function or downstream intracellular mediators of NMDA receptor function could also conceivably foster neural plasticity and even increased neural connectivity, given the evidence that D-cycloserine enhances memory consolidation in both experimental animals and human su…”
Background
Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene.
Bu, D.-F., Erlander, M. G., Hitz, B. C., Tillakaratne, N. J. K., Kaufman, D. L., Wagner-McPherson, C., Evans, G. A., & Tobin, A. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2115 · Cited by 495
Treatment-Resistant Schizophrenia - The Role of Clozapine
Meltzer, H. Y. (1997) · Current Medical Research and Opinion · doi:10.1185/03007999709113338 · Cited by 493
Decreased Serum Levels of D-Serine in Patients With Schizophrenia
Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., 篠田, 直., Nakazato, M., Kumakiri, C., Okada, S.-I., Hasegawa, H., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.572 · Cited by 489
Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study
Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., AMBLER, D., Puglia, M., Maloney, A. E., Michael, E., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050756 · Cited by 479
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia.
Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindström, L., & Engberg, G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02242-x · Cited by 478
NMDA-dependent modulation of CA1 local circuit inhibition
Grunze, H., Rainnie, D., Hasselmo, M., Barkai, E., Hearn, E., McCarley, R., & Greene, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02034.1996 · Cited by 467
A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia
Zhang, Z. J., & Reynolds, G. P. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00188-8 · Cited by 460
Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia
Hashimoto, T., Bazmi, H. H., Mirnics, K., Wu, Q., Sampson, A. R., & Lewis, D. A. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07081223 · Cited by 457
Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia
Talbot, K., Eidem, W. L., Tinsley, C. L., Benson, M. A., Thompson, E. W., Smith, R. J., Hahn, C.-G., Siegel, S. J., Trojanowski, J. Q., Gur, R. E., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20425 · Cited by 457
Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. E. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455
Myelination of Cortical-hippocampal Relays During Late Adolescence
Benes, F. M. (1989) · Schizophrenia Bulletin · doi:10.1093/schbul/15.4.585 · Cited by 448
DTI and MTR abnormalities in schizophrenia: Analysis of white matter integrity
Kubicki, M. R., Park, H., Westin, C., Nestor, P. G., Mulkern, R. V., Maier, S. E., Niznikiewicz, M. A., Connor, E. E., Levitt, J. J., Frumin, M., et al. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.03.026 · Cited by 433
Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
BEASLEY, C., & REYNOLDS, G. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00122-3 · Cited by 426
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.
Kegeles, L., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J., Heertum, R. V. V., Cooper, T. B., Carlsson, A., & Laruelle, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00976-8 · Cited by 425
Modulation of N -methyl- d -aspartate receptor function by glycine transport
Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 418
Self-citation
Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium
Knable, M. B., Barci, B. M., Webster, M. J., Meador‐Woodruff, J. H., & Torrey, Ε. F. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001471 · Cited by 414
Density of Glutamic Acid Decarboxylase 67 Messenger RNA–ContainingNeurons That Express the N-Methyl-D-AspartateReceptor Subunit NR2A in the Anterior Cingulate Cortex in Schizophreniaand Bipolar Disorder
Woo, T.-U. W., Walsh, J. P., & Benes, F. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.649 · Cited by 411
A subclass of prefrontal γ-aminobutyric acid axon terminals are selectively altered in schizophrenia
Woo, T.-U. W., Whitehead, R. E., Melchitzky, D. S., & Lewis, D. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5341 · Cited by 410
Abnormal Glutamate Receptor Expression in the Medial Temporal Lobe in Schizophrenia and Mood Disorders
Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301312 · Cited by 408
Development of the prefrontal cortex during adolescence: Insights into vulnerable neural circuits in schizophrenia
Lewis, D. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00277-1 · Cited by 388
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
Heresco‐Levy, U., Javitt, D. C., Ebstein, R. P., Vass, Á., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.037 · Cited by 386
Mutational analysis of the glycine-binding site of the NMDA receptor: Structural similarity with bacterial amino acid-binding proteins
Kuryatov, A. (1994) · Neuron · doi:10.1016/0896-6273(94)90445-6 · Cited by 385
Ionotropic Glutamate Receptors and Expression of N-Methyl- d -Aspartate Receptor Subunits in Subregions of Human Hippocampus: Effects of Schizophrenia
Gao, X.-M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B., & Tamminga, C. A. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1141 · Cited by 381
Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins
Beasley, C. L., Zhang, Z. J., Patten, I., & Reynolds, G. P. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01360-4 · Cited by 374
Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia.
Numakawa, T., Yagasaki, Y., Ishimoto, T., Okada, T., Suzuki, T., Iwata, N., Ozaki, N., Taguchi, T., Tatsumi, M., Kamijima, K., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh280 · Cited by 373
Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders
Akbarian, S., & Huang, H. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.04.001 · Cited by 370
Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics
Benes, F., Vincent, S. L., Alsterberg, G., Bird, E. D., & SanGiovanni, J. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-03-00924.1992 · Cited by 365
What Happens After the First Episode? A Review of Progressive Brain Changes in Chronically Ill Patients With Schizophrenia
Hulshoff Pol, H. E., & Kahn, R. S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm168 · Cited by 364
Endogenous d ‐Serine in Rat Brain: N‐Methyl‐ d ‐Aspartate Receptor‐Related Distribution and Aging
Hashimoto, A., Nishikawa, T., Oka, T., & Takahashi, K. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03219.x · Cited by 363
Human Dysbindin (DTNBP1) Gene Expression inNormal Brain and in Schizophrenic Prefrontal Cortex and Midbrain
Weickert, C. S., Straub, R. E., McClintock, B., Matsumoto, M., Hashimoto, R., Hyde, T. M., Herman, M. M., Weinberger, D. R., & Kleinman, J. E. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.6.544 · Cited by 352
Comparison of Ketamine-Induced Thought Disorder in Healthy Volunteers and Thought Disorder in Schizophrenia
Adler, C. M., Malhotra, A. K., Elman, I., Goldberg, T. E., Egan, M. F., Pickar, D., & Breier, A. F. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.10.1646 · Cited by 337
Functional Comparison of d ‐Serine and Glycine in Rodents: The Effect on Cloned NMDA Receptors and the Extracellular Concentration
Matsui, T., Sekiguchi, M., Hashimoto, A., Tomita, U., Nishikawa, T., & Wada, K. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65010454.x · Cited by 334
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia
Conn, P. J., Lindsley, C. W., & Jones, C. K. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.006 · Cited by 330
A Specific Role for NR2A-Containing NMDA Receptors in the Maintenance of Parvalbumin and GAD67 Immunoreactivity in Cultured Interneurons
Kinney, J. W., Davis, C. N., Tabarean, I., Conti, B., Bartfai, T., & Behrens, M. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4722-05.2006 · Cited by 329
Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor.
Birch, P., Grossman, C., & Hayes, A. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90367-6 · Cited by 324
A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia
Bendikov, I., Nadri, C., Amar, S., Panizzutti, R., DEMIRANDA, J., Wolosker, H., & Agam, G. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.10.010 · Cited by 323
Differential Hippocampal Expression of Glutamic Acid Decarboxylase 65 and 67 Messenger RNA in Bipolar Disorder and Schizophrenia
Heckers, S., Stone, D., Walsh, J., Shick, J., Koul, P., & Benes, F. M. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.521 · Cited by 322
Principles of Long-Term Dynamics of Dendritic Spines
Yasumatsu, N., Matsuzaki, M., Miyazaki, T., Noguchi, J., & Kasai, H. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0603-08.2008 · Cited by 321
Glutamate acting on NMDA receptors stimulates neurite outgrowth from cerebellar granule cells
Pearce, I. A., Cambray-Deakin, M. A., & Burgoyne, R. D. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80525-2 · Cited by 314
Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder
Schumacher, J. H., Jamra, R. A., Freudenberg, J., Becker, T., Ohlraun, S., Otte, A., Tullius, M., Kovalenko, S., Bogaert, A. V. D., Maier, W., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001421 · Cited by 312
Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain.
Robinson, M. B., Blakely, R., Couto, R., & Coyle, J. T. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47823-4 · Cited by 306
Self-citation
N‐Acetylaspartylglutamate Selectively Activates mGluR3 Receptors in Transfected Cells
Wróblewska, B., Wroblewski, J. T., Sf, P., Surin, A. M., Sullivan, S. E., & Neale, J. H. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010174.x · Cited by 299
Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia
Lewis, D. A., Cho, R. Y., Carter, C. S., Eklund, K. E., Förster, S., Kelly, M. A., & Montrose, D. M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030395 · Cited by 291
Reduced Dendritic Spine Density in Auditory Cortex of Subjects with Schizophrenia
Sweet, R. A., Henteleff, R. A., Zhang, W., Sampson, A. R., & Lewis, D. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.67 · Cited by 290
Modulation of NMDA receptor function: implications for vertebrate neural development
Scheetz, A. J., & Constantine‐Paton, M. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.10.8050674 · Cited by 284
Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects
Benes, F. M., Vincent, S. L., Marie, A. S., & Khan, Y. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00328-4 · Cited by 276
Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis
Tsai, G. E., & Lin, P. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361452 · Cited by 269
A Single Dominant Gene Can Account for Eye Tracking Dysfunctions and Schizophrenia in Offspring of Discordant Twins
Holzman, P. S. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800310049006 · Cited by 269
Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients
Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L. H., & Iyo, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.04.023 · Cited by 267
Reciprocal Alterations in Pre- and Postsynaptic Inhibitory Markers at Chandelier Cell Inputs to Pyramidal Neurons in Schizophrenia
Volk, D. W. (2002) · Cerebral Cortex · doi:10.1093/cercor/12.10.1063 · Cited by 264
Decreased Somal Size of Deep Layer 3 Pyramidal Neurons in the Prefrontal Cortex of Subjects With Schizophrenia
Pierri, J. N., Volk, C. L. E., Auh, S., Sampson, A., & Lewis, D. A. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.466 · Cited by 257
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia.
Nilsson, L., Linderholm, K., Engberg, G., Paulson, L., Blennow, K., Lindström, L., Nordin, C., Karanti, A., Persson, P., & Erhardt, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.013 · Cited by 257
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
GOFF, D. C., Tsai, G. E., Manoach, D. S., & Coyle, J. T. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1213 · Cited by 243
Self-citation
Impairment of early cortical processing in schizophrenia: An event-related potential confirmation study
Javitt, D. C., Doneshka, P., Zylberman, I., Ritter, W., & Vaughan, H. G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90005-x · Cited by 236
MK‐801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex
Sharp, F. R., Jasper, P., Hall, J., Noble‐Haeusslein, L. J., & Sagar, S. M. (1991) · Annals of Neurology · doi:10.1002/ana.410300609 · Cited by 235
Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia
Wang, C., McInnis, J., Ross-Sanchez, M., Shinnick‐Gallagher, P., Wiley, J. L., & Johnson, K. M. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00384-0 · Cited by 234
Ionotropic Glutamate Receptor Binding and Subunit mRNA Expression in Thalamic Nuclei in Schizophrenia
Ibrahim, H. M., Hogg, A. J., Healy, D. J., Haroutunian, V. H., Davis, K. L., & Meador‐Woodruff, J. H. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1811 · Cited by 233
GABA Transporter-1 mRNA in the Prefrontal Cortex in Schizophrenia: Decreased Expression in a Subset of Neurons
Volk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R., & Lewis, D. A. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.256 · Cited by 221
Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic
Depoortère, R., Dargazanli, G., Estenne‐Bouhtou, G., Coste, A., Lanneau, C., Desvignes, C., Poncelet, M., Héaulme, M., Santucci, V., Decobert, M., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300772 · Cited by 220
Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia
Kristiansen, L. V., Beneyto, M., Haroutunian, V, & Meador-Woodruff, J. H. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001844 · Cited by 220
AN ANALYSIS OF FACTORS INFLUENCING MEASUREMENTS OF DOPAMINE, NORADRENALINE, GLUTAMATEDECARBOXYLASE AND CHOLINE ACETYLASE IN HUMAN POST-MORTEM BRAIN TISSUE
Spokes, E. G. (1979) · Brain · doi:10.1093/brain/102.2.333 · Cited by 216
Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration.
Kim, P. M., Aizawa, H., Kim, P. S., Huang, A. S., Wickramasinghe, S. R., Kashani, A., Barrow, R., Huganir, R., Ghosh, A., & Snyder, S. (2005) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0409723102 · Cited by 214
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213
Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (–)-(1 R, 4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039)
Fell, M. J., Svensson, K. A., Johnson, B. G., & Schoepp, D. D. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136861 · Cited by 204
Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia
Reynolds, G. P., Czudek, C., & Andrews, H. B. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90039-5 · Cited by 201
Modeling GABA Alterations in Schizophrenia: A Link Between Impaired Inhibition and Altered Gamma and Beta Range Auditory Entrainment
Vierling-Claassen, D., Siekmeier, P. J., Stufflebeam, S. M., & Kopell, N. (2008) · Journal of Neurophysiology · doi:10.1152/jn.00870.2007 · Cited by 200
Support for involvement of neuregulin 1 in schizophrenia pathophysiology
Petryshen, T. L., Middleton, F. A., Kirby, A. W., Aldinger, K. A., Purcell, S., Tahl, A. R., Morley, C. P., McGann, L., Gentile, K. L., Rockwell, G. N., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001608 · Cited by 196
Phencyclidine and related drugs bind to the activated receptor-channel complex in rat brain membranes
Fagg, G. E. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90719-1 · Cited by 194
Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia
Madeira, C., Freitas, M. E., Vargas-Lopes, C., Wolosker, H., & Panizzutti, R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.02.002 · Cited by 191
Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia
Evans, J. D. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.01.011 · Cited by 191
Epidemiology and Etiology
Roos, A. J. D. (2013) · Springer eBooks · doi:10.1007/978-3-642-36229-3_2 · Cited by 190
Type III Neuregulin-1 Is Required for Normal Sensorimotor Gating, Memory-Related Behaviors, and Corticostriatal Circuit Components
Chen, Y.-J. J., Johnson, M. A., Lieberman, M. D., Goodchild, R. E., Schobel, S., Lewandowski, N., Rosoklija, G., Liu, R.-C., Gingrich, J. A., Small, S., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1815-08.2008 · Cited by 188
Expression of NMDAR1, GluR1, GluR7, and KA1 Glutamate Receptor mRNAs Is Decreased in Frontal Cortex of “Neuroleptic‐Free” Schizophrenics: Evidence on Reversible Up‐Regulation by Typical Neuroleptics
Sokolov, B. P. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71062454.x · Cited by 186
The Relationship of Structural Alterations to Cognitive Deficits in Schizophrenia: A Voxel-Based Morphometry Study
Antonova, E., Kumari, V., Morris, R. G., Halari, R., Anilkumar, A. P., Mehrotra, R., & Sharma, T. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.036 · Cited by 178
Neuregulin1 (NRG1) Signaling through Fyn Modulates NMDA Receptor Phosphorylation: Differential Synaptic Function inNRG1+/−Knock-Outs Compared with Wild-Type Mice
Bjarnadóttir, M., Misner, D., Haverfield-Gross, S., Bruun, S., Helgason, V. G., Stefánsson, H., Sigmundsson, A., Firth, D. R., Nielsen, B., Stefansdottir, R., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4314-06.2007 · Cited by 176
Genetic variation in DTNBP1 influences general cognitive ability
Burdick, K. E., Lencz, T., Funke, B., Finn, C. T., Szeszko, P. R., Kane, J. M., Kucherlapati, R., & Malhotra, A. K. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi481 · Cited by 173
Composition of the Synaptic PSD-95 Complex
Döṣemeci, A., Makusky, A. J., Jankowska‐Stephens, E., Yang, X., Slotta, D. J., & Markey, S. P. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700040-mcp200 · Cited by 172
Dopamine receptors, neuroleptics, and schizophrenia
Snyder, S. H. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.4.460 · Cited by 169
DNA copy-number analysis in bipolar disorder and schizophrenia reveals aberrations in genes involved in glutamate signaling
Wilson, G. M., Flibotte, S., Chopra, V. S., Melnyk, B. L., Honer, W. G., & Holt, R. A. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi489 · Cited by 169
Downregulated Kynurenine 3-Monooxygenase Gene Expression and Enzyme Activity in Schizophrenia and Genetic Association With Schizophrenia Endophenotypes
Wonodi, I., Stine, O. C., Sathyasaikumar, K. V., Roberts, R. C., Mitchell, B. D., Hong, L. E., Kajii, Y., Thaker, G. K., & Schwarcz, R. M. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.71 · Cited by 168
Long‐term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism
Harris, L. W., Sharp, T., Gartlon, J. E., Jones, D. N. C., & Harrison, P. J. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02902.x · Cited by 162
Postnatal Phencyclidine Administration Selectively Reduces Adult Cortical Parvalbumin-Containing Interneurons
Wang, C. Z., Yang, S. F., Xia, Y., & Johnson, K. M. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301647 · Cited by 161
Molecular mechanisms underlying activity-dependent regulation of BDNF expression
Shieh, P. B., & Ghosh, A. (1999) · Journal of Neurobiology · doi:10.1002/(sici)1097-4695(199910)41:1 · Cited by 160
Genetic associations with schizophrenia: Meta-analyses of 12 candidate genes
Shi, J., Gershon, E. S., & Liu, C. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.06.016 · Cited by 159
Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia
Porter, R. H. P., Eastwood, S. L., & Harrison, P. J. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01404-7 · Cited by 158
Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia
Stefani, M. R., & Moghaddam, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.031 · Cited by 157
Modelling prefrontal cortex deficits in schizophrenia: implications for treatment
Pratt, J. A., Winchester, C. L., Egerton, A., Cochran, S., & Morris, B. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.24 · Cited by 154
Neuroimaging of cognitive disability in schizophrenia: Search for a pathophysiological mechanism
Ragland, J. D., Yoon, J. H., Minzenberg, M., & Carter, C. S. (2007) · International Review of Psychiatry · doi:10.1080/09540260701486365 · Cited by 151
Calcium binding protein markers of GABA deficits in schizophrenia — post mortem studies and animal models
Reynolds, G. P., Abdul-Monim, Z., Neill, J. C., & Zhang, Z. (2004) · Neurotoxicity Research · doi:10.1007/bf03033297 · Cited by 150
Effect of Phencyclidine in Chronic Schizophrenics
Itil, T. M., Keskiner, A., Kiremitci, N., & Holden, J. (1967) · Canadian Psychiatric Association Journal · doi:10.1177/070674376701200217 · Cited by 148
Clinical Efficacy of Clozapine in Treatment-Refractory Schizophrenia: An Overview
Kane, J. M. (1992) · The British Journal of Psychiatry · doi:10.1192/s0007125000296918 · Cited by 147
pLG72 Modulates Intracellular D-Serine Levels through Its Interaction with D-Amino Acid Oxidase
Sacchi, S., Bernasconi, M., Martineau, M., Mothet, J., Ruzzene, M., Pilone, M. S., Pollegioni, L., & Molla, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709153200 · Cited by 146
[3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics
Hanada, S., Mita, T., Nishino, N., & Tanaka, C. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90341-9 · Cited by 140
Critical Appraisal of DNA Microarrays in Psychiatric Genomics
Mirnics, K., Levitt, P. R., & Lewis, D. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.003 · Cited by 139
Serine racemase binds to PICK1: potential relevance to schizophrenia
Fujii, K., Maeda, K., Hikida, T., Mustafa, A., Balkissoon, R., Xia, J., Yamada, T., Ozeki, Y., Kawahara, R., Okawa, M., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001776 · Cited by 137
NMDA Receptor Antagonists Disinhibit Rat Posterior Cingulate and Retrosplenial Cortices: A Potential Mechanism of Neurotoxicity
Li, Q., Clark, S., Lewis, D. V., & Wilson, W. A. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03070.2002 · Cited by 132
NR2B Signaling Regulates the Development of Synaptic AMPA Receptor Current
Hall, B. J., Ripley, B. A., & Ghosh, A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3793-07.2007 · Cited by 130
Spatial Memory Deficits Induced by Perinatal Treatment of Rats with PCP and Reversal Effect of D-Serine
Andersen, J. D., & Pouzet, B. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300394 · Cited by 129
Ionotropic Glutamate Receptors as Therapeutic Targets in Schizophrenia
Coyle, J. T., Tsai, G. E., & GOFF, D. C. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606212 · Cited by 126
Self-citation
The influence of agonal status on some neurochemical activities of postmortem human brain tissue
Perry, E. K., Perry, R. H., & Tomlinson, B. E. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90334-2 · Cited by 125
No deficit in total number of neurons in the prefrontal cortex in schizophrenics
Thune, J. J., Uylings, H. B. M., & Pakkenberg, B. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00043-1 · Cited by 124
Sites of antagonist action on N-methyl-D-aspartic acid receptors studied using fluctuation analysis and a rapid perfusion technique
Mayer, M. L., Westbrook, G. L., & Vyklický, L. (1988) · Journal of Neurophysiology · doi:10.1152/jn.1988.60.2.645 · Cited by 123
Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients
Hazlett, E. A., Buchsbaum, M. S., Haznedar, M. M., Newmark, R. E., Goldstein, K. E., Zelmanova, Y., Glanton, C. F., Torosjan, Y., New, A. S., Lo, J. N., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.472 · Cited by 123
Selective reduction of a PDZ protein, SAP‐97, in the prefrontal cortex of patients with chronic schizophrenia
Toyooka, K., Iritani, S., Makifuchi, T., Shirakawa, O., Kitamura, N., Maeda, K., Nakamura, R., Niizato, K., Watanabe, M., Kakita, A., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01181.x · Cited by 121
Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats
Abekawa, T., Ito, K., Nakagawa, S., & Koyama, T. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0729-8 · Cited by 118
Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects
Spokes, E. G., Garrett, N., Rossor, M. N., & Iversen, L. L. (1980) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(80)90103-3 · Cited by 117
Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder
Pickard, B. S., Malloy, M. P., Christoforou, A., Thomson, P. A., Evans, K. L., Morris, S. W., Hampson, M. E., Porteous, D. J., Blackwood, D., & Muir, W. J. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001867 · Cited by 116
Activation of Medial Prefrontal Cortex by Phencyclidine is Mediated via a Hippocampo-prefrontal Pathway
Jodo, E., Suzuki, Y., Katayama, T., Hoshino, K.-Y., Takeuchi, S., Niwa, S., & Kayama, Y. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh168 · Cited by 116
A Genetic Variant of the Serine Racemase Gene Is Associated with Schizophrenia
Morita, Y., Ujike, H., Tanaka, Y., Otani, K., Kishimoto, M., Morio, A., Kotaka, T., Okahisa, Y., Matsushita, M., Morikawa, A., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.025 · Cited by 113
Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia
Ohnuma, T., Kato, H., Arai, H., Faull, R. L. M., McKenna, P. J., & Emson, P. C. (2000) · Neuroreport · doi:10.1097/00001756-200009280-00019 · Cited by 111
Dendritic spines shaped by synaptic activity
Segal, M., & Andersen, P. N. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00123-9 · Cited by 107
Prolonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex
Zhang, Y., Behrens, M. M., & Lisman, J. E. (2008) · Journal of Neurophysiology · doi:10.1152/jn.00079.2008 · Cited by 107
Deciphering the Disease Process of Schizophrenia: The Contribution of Cortical Gaba Neurons
Lewis, D. A., & Hashimoto, T. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78004-7 · Cited by 106
Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression
Kristiansen, L. V., & Meador‐Woodruff, J. H. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.06.012 · Cited by 106
The NMDA receptor co-agonists, d-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex
Balu, D. T., Basu, A. C., Corradi, J., Cacace, A. M., & Coyle, J. T. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.006 · Cited by 104
Self-citation
Pyramidal cell size reduction in schizophrenia: evidence for involvement of auditory feedforward circuits
Sweet, R. A., Bergen, S. E., Sun, Z., Sampson, A. R., Pierri, J. N., & Lewis, D. A. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.03.002 · Cited by 102
Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia
Tkachev, D., Mimmack, M. L., Huffaker, S. J., Ryan, M., & Bahn, S. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007334 · Cited by 101
D-Amino acid oxidase activity and expression are increased in schizophrenia
Burnet, P. W. J., Eastwood, S. L., Bristow, G. C., Godlewska, B. R., Sikka, P., Walker, M. A., & Harrison, P. J. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.47 · Cited by 101
Is the Dysbindin Gene (DTNBP1) a Susceptibility Gene for Schizophrenia?
Williams, N. M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi061 · Cited by 100
A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia
Mitelman, S. A., Brickman, A. M., Shihabuddin, L., Newmark, R. E., Hazlett, E. A., Haznedar, M. M., & Buchsbaum, M. S. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.04.070 · Cited by 99
Allelic association of G72/G30 with schizophrenia and bipolar disorder: A comprehensive meta-analysis
Shi, J., Badner, J. A., Gershon, E. S., & Liu, C. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.004 · Cited by 98
Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid
Erhardt, S., & Engberg, G. (2002) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.2002.00962.x · Cited by 91
Cellular heterogeneity in cerebral cortex: A study of the morphology of pyramidal neurones in visual areas of the marmoset monkey
Elston, G. N., Tweedale, R., & Rosa, M. G. P. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19991206)415:1 · Cited by 90
Self-citation
Phencyclidine induction of the hsp70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels
Sharp, F. R., Butman, M., Koıstınaho, J., Aardalen, K., Näkki, R., Massa, S. M., Swanson, R. A., & Sagar, S. M. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90345-x · Cited by 89
Does Ketamine-Mediated N-methyl-D-aspartate Receptor Antagonism Cause Schizophrenia-like Oculomotor Abnormalities?
Radant, A. D. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00030-x · Cited by 89
Expression of the NR2B‐NMDA receptor subunit and its Tbr‐1/CINAP regulatory proteins in postmortem brain suggest altered receptor processing in schizophrenia
Kristiansen, L. V., Patel, S. A., Haroutunian, V. H., & Meador‐Woodruff, J. H. (2010) · Synapse · doi:10.1002/syn.20754 · Cited by 87
Dysbindin (DTNBP1, 6p22.3) is Associated with Childhood-Onset Psychosis and Endophenotypes Measured by the Premorbid Adjustment Scale (PAS)
Gornick, M. C., Addington, A. M., Sporn, A. L., Gogtay, N., GREENSTEIN, D. K., Lenane, M., Gochman, P., Ordóñez, A. E., Balkissoon, R., Vakkalanka, R., et al. (2005) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-005-0028-3 · Cited by 85
Postnatal phencyclidine‐induced deficit in adult water maze performance is associated with N‐methyl‐ d ‐aspartate receptor upregulation
Sircar, R. (2003) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(03)00026-1 · Cited by 81
GluR5,6,7 subunit immunoreactivity on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic depressives
Benes, F. M., Todtenkopf, M. S., & Kostoulakos, P. (2001) · Hippocampus · doi:10.1002/hipo.1065 · Cited by 79
Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: A HuGE review and meta-analysis
Li, D., & He, L. (2007) · Genetics in Medicine · doi:10.1097/01.gim.0000250507.96760.4b · Cited by 79
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia
Coyle, J. T., Balu, D. T., Benneyworth, M. A., Basu, A. C., & Roseman, A. S. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.3/jcoyle · Cited by 75
Self-citation
Kynurenic Acid And Schizophrenia
Erhardt, S., Schwieler, L., & Engberg, G. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0135-0_18 · Cited by 74
Preliminary evidence for a link between schizophrenia and NMDA–glycine site receptor ligand metabolic enzymes, d -amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1)
Kapoor, R., Lim, K. S., Cheng, A., Garrick, T. M., & Kapoor, V. (2006) · Brain Research · doi:10.1016/j.brainres.2006.05.082 · Cited by 73
Association between the ionotropic glutamate receptor kainate 3 (GRIK3) ser310ala polymorphism and schizophrenia
Begni, S., Popoli, M., Moraschi, S., Bignotti, S., Tura, G. B., & Gennarelli, M. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000987 · Cited by 71
Dr. Snyder Replies
Snyder, S. H. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.7.992 · Cited by 69
Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR
Fricker, A.-C., Mok, M. H. S., de la Flor, R., Shah, A. J., Woolley, M. L., Dawson, L. A., & Kew, J. N. C. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.03.002 · Cited by 68
Cortical Glutamatergic Markers in Schizophrenia
Scarr, E., Beneyto, M., Meador‐Woodruff, J. H., & Dean, B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300758 · Cited by 67
NAAG Reduces NMDA Receptor Current in CA1 Hippocampal Pyramidal Neurons of Acute Slices and Dissociated Neurons
Bergeron, R., Coyle, J. T., Tsai, G., & Greene, R. W. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300559 · Cited by 64
Self-citation
Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia
Huerta, I., McCullumsmith, R. E., Haroutunian, V. H., Giménez‐Amaya, J. M., & Meador‐Woodruff, J. H. (2006) · Synapse · doi:10.1002/syn.20250 · Cited by 60
Evidence for association and epistasis at the DAOA/G30 and D ‐amino acid oxidase loci in an Irish schizophrenia sample
Corvin, A. P., McGhee, K. A., Murphy, K., Donohoe, G. J., Nangle, J. M., Schwaiger, S., KENNY, N. W., Clarke, S., Meagher, D. J., Quinn, J. P., et al. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30452 · Cited by 59
Differential alterations of kainate receptor subunits in inhibitory interneurons in the anterior cingulate cortex in schizophrenia and bipolar disorder
Woo, T.-U. W., SHRESTHA, K., AMSTRONG, C., Minns, M., WALSH, J., & Benes, F. M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.06.023 · Cited by 58
Association of DAAO with schizophrenia in the Chinese population
Liu, X., He, G., Wang, X., Chen, Q., Qian, X., Lin, W., Li, D., Gu, N., Feng, G., & He, L. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.07.078 · Cited by 53
Polymorphism in the 5′-promoter region of serine racemase gene in schizophrenia
Goltsov, A. Y., Loseva, J. G., Андреева, Т. В., Grigorenko, A. P., Abramova, L. I., Каледа, В. Г., Александровна, О. В., Moliaka, Y. K., & Rogaev, E. I. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001801 · Cited by 50

Sorted by citations

The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue
Brisch, R., Saniotis, A., Wolf, R. J., Bielau, H., Bernstein, H., Steiner, J. H., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 575
The touchscreen operant platform for testing learning and memory in rats and mice
Horner, A. E., Heath, C. J., Hvoslef‐Eide, M., Kent, B. A., Kim, C. H., Nilsson, S. R. O., Alsiö, J., Oomen, C. A., Holmes, A., Saksida, L. M., et al. (2013) · Nature Protocols · doi:10.1038/nprot.2013.122 · Cited by 412
Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
Millan, M. J., Fone, K. C. F., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 376
Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis
Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304
Reviewing the ketamine model for schizophrenia
Frohlich, J., & Van Horn, J. D. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512909 · Cited by 303

See all 184

Authors: Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G.
Affiliations: Harvard University (US)
Corresponding author: Coyle, Joseph T.
ORCID: Coyle, Joseph T.
Benneyworth, Michael
Balu, Darrick
Venue: Handbook of Experimental Pharmacology
Publisher: Springer Berlin Heidelberg
Published: 2012
Issue: 213
Pages: 267-295
ISSN: 0171-2004 (ISSN-L)
1865-0325
DOI: 10.1007/978-3-642-25758-2_10
PMC: PMC4817347
OpenAlex: W1872072116
Cited by: 180
References: 216
Citations by year: 2026: 7 · 2025: 7 · 2024: 6 · 2023: 4 · 2022: 13 · 2021: 19 · 2020: 10 · 2019: 9 · 2018: 10 · 2017: 11 · 2016: 11 · 2015: 21 · 2014: 25 · 2013: 22 · 2012: 4
FWCI: 81.63
Type: book chapter
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Handbook of experimental pharmacology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: U.S. Public Health Service
National Institute of Mental Health (P50MH060450, R01 MH51290, R01MH051290, F32MH090697, P50MH06045)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: schizophrenia, NMDA receptor hypofunction, ketamine, dissociative anesthetics, postsynaptic density, D-amino acid oxidase, G72, dysbindin, neuregulin, parvalbumin interneurons, cognitive impairment, negative symptoms, psychosis, dopamine release, glutamatergic neurotransmission
MeSH terms: Animals, Cognition, gamma-Aminobutyric Acid, Humans, Ketamine, Synaptic Transmission, Schizophrenia, Synapses, Receptors, N-Methyl-D-Aspartate, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks